Title | Pharyngeal Electrical Stimulation for Acute Stroke dysphagia Trial |
Acronym | PhEAST |
Short title | Pharyngeal Electrical Stimulation for Post Stroke dysphagia |
Chief investigator | Professor Philip M Bath |
Objectives |
Overall
|
Trial configuration | International prospective randomised open-label blinded-endpoint (PROBE) parallel group superiority phase IV effectiveness trial |
Setting | Secondary care: acute stroke services |
Sample size estimate |
The null hypothesis is that PES does not alter DSRS at day 14 post recruitment in participants with PSD. The primary outcome, DSRS (dysphagia severity rating scale) will be compared between PES and no PES using multiple linear regression with adjustment for stratification and minimisation variables. Assuming alpha 5%, power 90%; DSRS difference 1.2, standard deviation 5.0; losses 3%, crossovers 3%; sample rounded up, a sample size of N=800 is needed (PES n=400, control n=400) (assumptions based on pilot trials and STEPS trial). |
Number of participants | 800 |
Eligibility criteria |
Inclusion:
800 hospitalised adults (age ≥18) with recent (4-31 days) ischaemic or haemorrhagic anterior or posterior circulation stroke (as diagnosed clinico-radiologically) at a stroke centre, and clinical dysphagia defined as a functional oral intake scale (FOIS) score of 1 (nothing by mouth, feeding by naso-gastric tube [NGT]/percutaneous endoscopic gastrostomy [PEG] tube) or 2 (tube dependent with minimal attempts of food or liquids). NIHSS item 1a score of 0, 1 or 2 (where the patient requires repeated stimulation to arouse). Excluded: Non-stroke dysphagia, e.g., due to traumatic brain haemorrhage, subarachnoid haemorrhage, brain tumour, Parkinson's disease, multiple sclerosis, severe dementia, head or neck cancer. NIHSS item 1a score of 2 (where the patient only responds to pain) or NIHSS item 1a score of 3. Pre-stroke dysphagia or dependency (modified Rankin scale, mRS 4/5). Patient expected to be repatriated to a separate organisation. Patient expected to be rehabilitated at a separate organisation. Patient not likely to be in the treating hospital for at least 14 days. Ongoing or anticipated ventilation/intubation/tracheostomy or use of electrical or magnetic stimulation. Malignant middle cerebral artery syndrome. Pregnant. Pacemaker. Need for >35 litres of oxygen. Two or more NGT pulled out unless nasal bridle in place. Investigator feels patient will not tolerate PES catheter. |
Description of interventions |
Intervention arm
PES on top of guideline-based standard-of-care. PES will be administered on days 1-6 using a commercial catheter with integral feeding tube. PES involves six daily 10 minute treatments at 5 Hz; threshold and tolerability currents will be assessed and the treatment current set at threshold + 0.75 x (tolerability - threshold) with current generated by a base-station. Dosing levels will be monitored, and sites informed if the stimulation current is too low, i.e. <20 mA; sites will be re-trained on the importance of delivering adequate current, if necessary. The catheter will be replaced once only if pulled out before 3 treatments have been administered. Treatment will be administered by PES-trained research coordinators, nurses or SLTs who are not involved in outcome data collection. Comparator armNo PES catheter/stimulation on top of best guideline-based standard-of-care dysphagia management. A standard NGT will be used for feeding as necessary. |
Duration of study | From randomisation: treatment for 6 days, primary outcome at day 14, final follow-up at day 90. Trial and funding 3.25 years. Secondary endpoint at Day 365 (all cause mortality). |
Randomisation and blinding | Randomised 1:1 with stratification on country and minimisation on age, sex, dysphagia severity rating scale (DSRS), impairment (National Institutes of Health stroke scale [NIHSS]), stroke type (ischaemic/haemorrhagic), circulation (anterior/posterior), time to randomisation; with 10% simple randomisation. Treatment will be delivered by a dedicated member of staff not otherwise involved in the trial. Outcomes will be assessed by other staff blinded to randomised treatment. |
Outcome measures |
Primary at day 14±1
Secondary at day 7±1
Secondary at day 14±1 Note 1: We have included several measures of dysphagia and feeding: DSRS, FOIS, EAT-10 and FSS to triangulate the presence and magnitude of dysphagia and effects on feeding. These will be analysed together using the Wei-Lachin test.
Secondary at discharge/death by hospital assessor blinded to treatment:
Secondary at day 90±7 by central telephone assessor blinded to
baseline, treatment and in-hospital data (or by post)
Secondary at day 365
Safety
Costs |
Statistical methods |
The primary outcome, DSRS, will be compared between PES and no PES using multiple linear regression with adjustment for stratification and minimisation variables. The null hypothesis is that PES does not alter DSRS at day 14 in participants with PSD. Assuming alpha 5%, power 90%; DSRS difference 1.2, standard deviation 5.0; losses 3%, crossovers 3%; sample rounded up, a sample size of N=800 is needed (PES n=400, control n=400). |
Trial |
Delay to PhEAST (patients cannot be enrolled into PhEAST after number of days shown, after enrolment into the other study) |
ENOS-2 | ≥ 4 days |
MAPS-2 | ≥ 4 days |
ReCAST-3 | ≥ 14 days |
TICH-3 | ≥ 14 days |
ProFATE (NUH) | ≥ 14 days |
MACE-ICH (NUH) | ≥ 14 days |
For any queries, please email us.